

**Ad hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)**

**WILEX enters into licensing and development partnership for
MESUPRON® in China with Link Health Group**

Munich, Germany, 28 March 2014 – WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that it has entered into a licensing and development partnership for MESUPRON® with Link Health Co., Guangzhou, China. Link Health will receive the exclusive licensing rights for the development and marketing of MESUPRON® in China, Hong Kong, Taiwan and Macao.

Link Health will be responsible for performing and financing the entire clinical development of MESUPRON® in China in all oncological indications, including HER2-negative metastatic breast cancer and non-metastatic pancreatic cancer, as well as for the regulatory process and product marketing. To receive regulatory approval from the SFDA (Chinese State Food and Drug Administration), the complete clinical development programme from Phase I to Phase III must also be conducted in China, one of the largest pharmaceutical markets with rapid growth rates. The data generated may be used to support potential further development of MESUPRON® in other key markets.

Under the agreement, WILEX will receive a signing fee and milestone payments totalling more than 7 million Euro during clinical development in the first four indications to be developed by Link Health as well as staggered medium single digit royalties. The initial fees received by WILEX under the cooperation will not materially influence the current cash reach of the company.

+++ End of Ad hoc release +++

Information on MESUPRON® and the uPA-programme

WILEX has developed with MESUPRON® (INN: Upamostat) a drug candidate to inhibit the Urokinase Plasminogen Activator (uPA) system. The uPA system has been shown to play a key role in tumour cell invasion and metastasis, as well as in primary tumour growth, of various solid tumours. In the Company's view, the uPA inhibitor MESUPRON® of WILEX can be considered as a promising new non-cytotoxic approach in cancer therapy to prolong progression free survival and to specifically block tumour metastasis in solid cancers. Data from two Phase IIa trials (proof of concept) in locally advanced pancreatic cancer (2010) and metastatic breast cancer (2012) indications show the safety and activity of the drug candidate in combination with chemotherapeutic agents.

About WILEX

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company's portfolio includes diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer based on antibodies and small molecules. Our aim is out-licensing these clinical projects. The subsidiary Heidelberg Pharma GmbH in Ladenburg, Germany, offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Our customers and partners include leading international pharmaceutical companies. WILEX AG is listed at the Frankfurt Stock Exchange: ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available at www.wilex.com.

Contact

WILEX AG

Sylvia Wimmer

Tel.: +49 (0)89-41 31 38-29

Email: [investors\[at\]wilex.com](mailto:investors[at]wilex.com)

Grillparzerstr. 10, 81675 Munich, Germany

For press enquiries

MC Services AG

Katja Arnold (CIRO)

Tel.: +49-89-210 228-40

Mobil: +49 160 9360 3022

E-Mail: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.